Validation of liquid biopsy for ESR1-mutation analysis in hormone-sensitive breast cancer: a pooled meta-analysis

被引：5
作者：
Najim, Omar [1 ,2 ]
Papadimitriou, Konstantinos [1 ,2 ,3 ]
Broeckx, Glenn [1 ,2 ,4 ]
Huizing, Manon [2 ,5 ]
Tjalma, Wiebren [1 ,2 ,6 ]
机构：
[1] Univ Antwerp, Univ Antwerp Hosp, Multidisciplinary Breast Clin, Edegem, Belgium
[2] Univ Antwerp, Fac Med, Edegem, Belgium
[3] Antwerp Univ Hosp, Dept Med Oncol, Edegem, Belgium
[4] Antwerp Univ Hosp, Dept Pathol, Edegem, Belgium
[5] Antwerp Univ Hosp, Biobank, Edegem, Belgium
[6] Univ Antwerp, Antwerp Univ Hosp, Dept Obstet & Gynecol, Unit Gynecol Oncol, Edegem, Belgium
来源：
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词：
ESR1; liquid biopsy; next-generation sequencing; digital PCR; metastasized breast cancer; CIRCULATING TUMOR DNA; ACTIVATING ESR1 MUTATIONS; ACQUIRED-RESISTANCE; PLASMA; EVOLUTION; EMERGENCE; THERAPY;
D O I：
10.3389/fonc.2023.1221773
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Several retrospective and prospective studies have shown that genomic alterations in Estrogen-receptor one (ESR1) can be characterized not only in tissue samples but also by sequencing circulating tumor DNA (ctDNA) in liquid biopsy. Therefore, liquid biopsy is a potential noninvasive surrogate for tissue biopsy. This meta-analysis was designed to compare the prevalence of ESR 1 mutation detected with liquid biopsy and tissue biopsy. A pooled meta-analysis of studies published between 1 January 2007 and 1 March 2021 was conducted regarding the methodologies used for ESR1 mutation analysis. Liquid biopsy is a valid, inexpensive, and attractive noninvasive alternative to tumor biopsies for the identification of ESR1 mutations. Liquid biopsy for ESR 1 analysis would facilitate regular testing, allowing monitoring of the sensitivity to ET and guiding treatment strategies.
引用
收藏
页数：12
相关论文
共 60 条
  • [11] Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer A Secondary Analysis of the BOLERO-2 Clinical Trial
    Chandarlapaty, Sarat
    Chen, David
    He, Wei
    Sung, Patricia
    Samoila, Aliaksandra
    You, Daoqi
    Bhatt, Trusha
    Patel, Parul
    Voi, Maurizio
    Gnant, Michael
    Hortobagyi, Gabriel
    Baselga, Jose
    Moynahan, Mary Ellen
    [J]. JAMA ONCOLOGY, 2016, 2 (10) : 1310 - 1315
  • [12] Endocrine resistance in breast cancer - An overview and update
    Clarke, Robert
    Tyson, John J.
    Dixon, J. Michael
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2015, 418 : 220 - 234
  • [13] Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor
    Clatot, Florian
    Perdrix, Anne
    Augusto, Laetitia
    Beaussire, Ludivine
    Delacour, Julien
    Calbrix, Celine
    Sefrioui, David
    Viailly, Pierre-Julien
    Bubenheim, Michael
    Moldovan, Cristian
    Alexandru, Cristina
    Tennevet, Isabelle
    Rigal, Olivier
    Guillemet, Cecile
    Leheurteur, Marianne
    Gouerant, Sophie
    Petrau, Camille
    Thery, Jean-Christophe
    Picquenot, Jean-Michel
    Veyret, Corinne
    Frebourg, Thierry
    Jardin, Fabrice
    Sarafan-Vasseur, Nasrin
    Di Fiore, Frederic
    [J]. ONCOTARGET, 2016, 7 (46) : 74448 - 74459
  • [14] Cell-free circulating tumour DNA as a liquid biopsy in breast cancer
    De Mattos-Arruda, Leticia
    Caldas, Carlos
    [J]. MOLECULAR ONCOLOGY, 2016, 10 (03) : 464 - 474
  • [15] Liquid Biopsies: Genotyping Circulating Tumor DNA
    Diaz, Luis A.
    Bardelli, Alberto
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (06) : 579 - +
  • [16] The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
    Diaz, Luis A., Jr.
    Williams, Richard T.
    Wu, Jian
    Kinde, Isaac
    Hecht, J. Randolph
    Berlin, Jordan
    Allen, Benjamin
    Bozic, Ivana
    Reiter, Johannes G.
    Nowak, Martin A.
    Kinzler, Kenneth W.
    Oliner, Kelly S.
    Vogelstein, Bert
    [J]. NATURE, 2012, 486 (7404) : 537 - 540
  • [17] Plasma next generation sequencing and droplet digital PCR-based detection of epidermal growth factor receptor (EGFR) mutations in patients with advanced lung cancer treated with subsequent-line osimertinib
    Ding, Pei N.
    Becker, Therese
    Bray, Victoria
    Chua, Wei
    Ma, Yafeng
    Xu, Bo
    Lynch, David
    de Souza, Paul
    Roberts, Tara
    [J]. THORACIC CANCER, 2019, 10 (10) : 1879 - 1884
  • [18] ESR1 mutations in breast cancer
    Dustin, Derek
    Gu, Guowei
    Fuqua, Suzanne A. W.
    [J]. CANCER, 2019, 125 (21) : 3714 - 3728
  • [19] Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA
    Forshew, Tim
    Murtaza, Muhammed
    Parkinson, Christine
    Gale, Davina
    Tsui, Dana W. Y.
    Kaper, Fiona
    Dawson, Sarah-Jane
    Piskorz, Anna M.
    Jimenez-Linan, Mercedes
    Bentley, David
    Hadfield, James
    May, Andrew P.
    Caldas, Carlos
    Brenton, James D.
    Rosenfeld, Nitzan
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (136)
  • [20] Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer
    Fribbens, Charlotte
    O'Leary, Ben
    Kilburn, Lucy
    Hrebien, Sarah
    Garcia-Murillas, Isaac
    Beaney, Matthew
    Cristofanilli, Massimo
    Andre, Fabrice
    Loi, Sherene
    Loibl, Sibylle
    Jiang, John
    Bartlett, Cynthia Huang
    Koehler, Maria
    Dowsett, Mitch
    Bliss, Judith M.
    Johnston, Stephen R. D.
    Turner, Nicholas C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (25) : 2961 - 2968
123456